Trombositozun Bir Nedeni; 5q Sendromu

Miyelodisplastik sendromlar MDS periferik kanda değişik derecelerde sitopeni, hematopoetik hücrelerde morfolojik ve fonksiyonel anormalliklerle karakterize, akut lösemiye ilerleme riski yüksek, kemik iliğinin klonal bir grup hematolojik malignitesidir. Trombositoz; trombosit sayısının 450.000/mm3 üzerinde olması olarak tanımlanır. Aşırı trombositoz ise trombosit sayısının 1.000.000/mm3olmasıdır. Miyelodisplastik sendromlar çoğunlukla sitopeni ile görülmektedir. Trombositoz, MDSʼde trombositopeniden daha az görülür. Trombositoz; 5q sendromunda, 3q21q26 sendromunda ve MDS / MPNʼde, genellikle JAK2ʼde ve ayrıca SF3B1ʼin aktive edici mutasyonları ile ilişkili halka sideroblastları ve trombositozu daha önce RARS-T olarak adlandırılır bulunan MDS / MPNʼde tarif edilmiştir. Burada aşırı trombositozun bir nedeninin de 5q sendromu olabileceğini vurgulamak üzere olgumuzu yayınlamak istedik

Anahtar Kelimeler:

Miyelodisplastik sendromlar, 5q sendrom, Trombositoz, Anemi, Displazi

A Cause of Thrombocytosis; 5q Syndrome

Myelodysplastic syndromes MDS are hematological malignancies of bone marrow with a high risk of progression to acute leukemia and characterized by morphological and functional abnormalities in hematopoietic cells. thrombocytosis; is defined as the number of platelets above 450.000/mm3. Excessive thrombocytosis is a platelet count of 1.000.000/mm3. Myelodysplastic syndromes are mostly presented with cytopenia. Thrombocytosis is less commonly seen in MDS than thrombocytopenia. Thrombocytosis has been described in 5q- syndrome, 3q21q26 syndrome, and in MDS/MPN with ring sideroblasts and thrombocytosis previously called RARS-T which is often associated with activating mutations in JAK2 as well as SF3B1. We wanted to publish our case to emphasize that 5q syndrome may be a cause of extrem thrombocytosis

Keywords:

Myelodysplastic syndromes, 5q syndrome, Thrombocytosis, Anemia, Dysplasia,

PDF

___

Demircioğlu S, Ekinci Ö, Doğan A, Demir C. Yaşlı hastada miyelodisplastik sendrom. Hematolojide geriatrik yaklaşım. Türkiye Klinikleri 2018; Supll:60-4.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20):2391-405.
Kumar A, Jain M, Kushwaha R, Singh US. Anemia with thrombocytosis in an elderly male: A case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis. Hematology Transfusion and Cell Therapy 2018; 40(4):385-8.
Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994; 84(10):3253-60.
Lee JH, List A, Sallman DA. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Eur J Haematol 2019; 102(3):203-9.
Washington LT, Jilani I, Estey E, Albitar M. Less apoptosis in patients with 5q syndrome than in patients with refractory anemia. Leuk Res 2002; 26(10):899-902.
Takahashi H, Furukawa T, Hashimoto S, Kanazawa N, Satoh N, Suzuki N, Takizawa J, Uesugi Y, Takahashi M, Aizawa Y, Koike T. 5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: A case report. Am J Hematol 2000; 64(2):120-3.
Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology 2004; 9(4):271-7.
Pellagatti A, Boultwood J. Recent advances in the 5q- syndrome. Mediterr J Hematol Infect Dis 2015; 7(1):e2015037.
Cabello AI, Collado R, Ruiz MA, Martínez J, Navarro I, Ferrer R, Sosa AM, Carbonell F. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: Reclassification of the cases by WHO proposals. Leuk Res 2005; 29(4):365-70.
Griva E, Goumakou E, Papadhimitriou S, Galanopoulos A, Leviada A, Tsourveloudis I, Tsakiridou A, Anagnostopoulos N. Myelodysplastic syndromes with thrombocytosis: A report from single centre. Haema 2004; 7(3):352-6.
Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC, Noel P. The 5q- syndrome: A singleinstitution study of 43 consecutive patients. Blood 1993; 81(4):1040-5.